Travere Therapeutics, Inc. (TVTX) Dividend History

Company News

• Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

  Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition. If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS.

  GlobeNewswire Inc.
• Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Travere Therapeutics announced that it granted inducement equity grants covering 115,100 shares of its common stock to ten new employees, consisting of stock options and restricted stock units. These grants were made as inducements to the new employees to join the company.

  GlobeNewswire Inc.
• Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  Travere Therapeutics, a biopharmaceutical company focused on rare diseases, announced that its president and CEO will present at the upcoming J.P. Morgan Healthcare Conference.

  GlobeNewswire Inc.
• Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Travere Therapeutics announced that it granted inducement equity grants to six new employees, consisting of restricted stock units covering 24,400 shares of its common stock. The RSUs vest over four years, subject to the new employees' continued service.

  GlobeNewswire Inc.
• Travere Therapeutics Announces Pricing of Public Offering of Common Stock

  Travere Therapeutics announced the pricing of a public offering of 7,812,500 shares of its common stock at $16.00 per share, raising $125 million in gross proceeds. The offering is expected to close on November 12, 2024.

  Benzinga